These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21618260)

  • 1. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Hongthanakorn C; Chotiyaputta W; Oberhelman K; Fontana RJ; Marrero JA; Licari T; Lok AS
    Hepatology; 2011 Jun; 53(6):1854-63. PubMed ID: 21618260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
    Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
    PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs.
    Chotiyaputta W; Hongthanakorn C; Oberhelman K; Fontana RJ; Licari T; Lok AS
    J Viral Hepat; 2012 Mar; 19(3):205-12. PubMed ID: 22329375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug resistance, genotype, and serotype of hepatitis B virus in nucleos(t)ide analogue naive patients with chronic hepatitis B].
    Li XG; Xu J; Liu BM; Yang JX; Yan L; Li T; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):92-5. PubMed ID: 20196945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
    Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B.
    Sayan M; Akhan SC; Meric M
    J Viral Hepat; 2010 Jan; 17(1):23-7. PubMed ID: 19566788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China.
    Li XG; Liu BM; Xu J; Liu XE; Ding H; Li T
    J Med Virol; 2012 Feb; 84(2):207-16. PubMed ID: 22170539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
    Chotiyaputta W; Peterson C; Ditah FA; Goodwin D; Lok AS
    J Hepatol; 2011 Jan; 54(1):12-8. PubMed ID: 20888661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.